BOTHELL, Wash., April 08, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced the appointment of Nadia Dac as chief commercial officer (CCO), effective April 8, 2019. She will report to Bob Azelby, Alder’s president and chief executive officer.
“Nadia brings an impressive degree of relevant commercial experience with prior leadership roles in marketing and sales at global biopharmaceutical companies, including a track record of successfully launching multiple novel neurology products in competitive markets,” said Bob Azelby. “We are excited to have Nadia join the Alder team. Her strategic and commercial capabilities will be a great asset to Alder as we continue to prepare to commercialize eptinezumab for migraine prevention and advance our pipeline.”
Ms. Dac brings more than 25 years of U.S. and global commercial experience with both large and small publicly traded biopharmaceutical companies, with extensive expertise across all commercial functions including marketing, market access and promotion, sales, pipeline management, business development and partnerships. She joins Alder from AbbVie, where she served as vice president of global specialty commercial development. In this role, she was instrumental in driving the optimization of assets within the specialty pipeline portfolio, including the in-licensing and commercial development of the global neuroscience, women’s health, virology and cystic fibrosis portfolios. Prior to AbbVie, Ms. Dac held several roles of increasing responsibility at Novartis, where she was head of the Multiple Sclerosis (MS) franchise, building the sales organization that successfully launched Gilenya®, Extavia® and Ilaris®. Before Novartis, Ms. Dac held several marketing roles, including leading marketing for Biogen’s MS products, Tysabri® and Avonex®, and for Pfizer’s Alzheimer's disease product, Aricept®. Previously, Ms. Dac spent several years in marketing and sales roles at Johnson & Johnson and Eli Lilly and Company.
“I’m thrilled to join the Alder team at such an exciting and pivotal moment for the company and the migraine community, as the company has the potential to transform the treatment paradigm for migraine patients,” said Ms. Dac. “I look forward to working with the Alder team as we prepare for the expected approval and launch of eptinezumab in the first quarter of 2020, and to contribute to the growth of Alder as it scales the organization into a fully integrated biopharmaceutical company.”
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com .
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements relating to: the potential approval, launch and commercialization of eptinezumab; the advancement of Alder’s pipeline; Alder’s potential to transform the treatment paradigm for migraine patients; and Alder’s continued growth into a fully integrated biopharmaceutical company. Words such as “will,” “continue,” “prepare,” “advance,” “potential,” “transform,” “look forward,” “expected,” “contribute,” “growth,” “scales,” or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements in this press release are based upon Alder's current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the build of Alder’s commercialization infrastructure; risks and uncertainties relating to the manufacture and supply of eptinezumab; Alder’s ability to develop and advance programs in its pipleline; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption "Risk Factors" in Alder's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, which was filed with the Securities and Exchange Commission (SEC) on February 25, 2019, and is available on the SEC's website at www.sec.gov. Additional information will also be set forth in Alder's other reports and filings it will make with the SEC from time to time. The forward-looking statements made in this press release speak only as of the date of this press release. Alder expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Alder's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact:
Michael Schaffzin Stern Investor Relations, Inc. 212-362-1200 michael@sternir.com
Media Contact:
Ashley Cadle TogoRun 310-463-0143 a.cadle@togorun.com
All trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
